SANDBOX-&-CO
Sandbox & Co, a London-based group operating a network of learning businesses, today announced that it has acquired award-winning UK-based children’s subscription service, toucanBox, which will sit within its newest division, Sandbox Experiences.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005015/en/
Virginie Charles-Dear, Founder and CEO of toucanBox, UK-based children’s subscription service, that is now part of Sandbox & Co.’s rapidly expanding portfolio (Photo: Business Wire)
Inspired by Montessori learning and championing STEAM (science, technology, engineering, art, and maths), the newly acquired toucanBox provides fun educational opportunities for children aged 3 to 8 yrs. Through custom boxes posted through the letterbox, on a subscription or buy it now basis, it delivers craft materials and activities that help develop children’s key skills and support their cognitive and language development, fine motor skills and mental wellbeing.
‘We have been big fans of toucanBox and feel it is a perfect complement to our existing range of hands-on educational tools.’ said Bhav Singh, founder and CEO of Sandbox. ‘Creativity-filled fun learning is at the heart of what we do and I can’t wait to start working together on new experiences that will keep our users delighted and entertained.’
toucanBox will be joining the company’s new division, Sandbox Experiences, that currently includes Brazilian children’s book club, Leiturinha. Drawing on his expertise in growing Leiturinha into the largest kids book subscription service in Brazil, Sandbox Experiences’ lead, Guilherme Martins, will be focusing on rolling out new products across new markets, including in the USA and Europe.
‘Our goal is to deliver fun-filled learning opportunities for children aged 0-12 around the world’, said Guilherme Martins, president at Sandbox Experiences. ‘toucanBox is the perfect extension to our existing offering and I look forward to collaborating with the team on delivering even more engaging educational opportunities to help improve learning worldwide.’
‘toucanBox is all about learning through hands-on, fun activities and we are excited to join forces with Sandbox to accelerate our growth and pursue our mission to unleash children’s creativity’, said Virginie Charles-Dear, Founder and CEO of toucanBox. ‘We’re looking forward to expanding our product range further and reaching even more families in Europe and across the world.’
Sandbox has seen rapid growth over the last 5 years, and its current portfolio now consists of 18 brands with a peak monthly audience of 65M+ kids, families, and teachers. Its award-winning properties include Code Kingdoms, online coding courses for kids, Hopster, preschool learning platform, and Spanish companies Edujoy and Tellmewow. The company has been acquisitive and continues to focus on its buy and build strategy.
For logo and images click HERE
About Sandbox & Co – https://sandboxandco.com
Sandbox & Co is a London-based group operating a network of learning businesses providing an unparalleled ecosystem of edutainment products that reaches over 65 million children, their parents, and teachers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005015/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom